
TRVI Stock Forecast & Price Target
TRVI Analyst Ratings
Bulls say
Trevi Therapeutics is well-positioned for success due to its strong financial position, clear regulatory pathway, and diverse multi-indication strategy for its potential first-in-class therapy, Haduvio. Positive clinical data and a scalable development approach have significantly de-risked the outlook for Haduvio and its potential commercial success, with a runway for funding trials extending into 2028. However, there are still potential risks to consider, such as competition from a similar therapy from GSK expected to readout in 3Q26, and the need for additional financing for the large IPF cough Phase 3 study. Overall, as a financial analyst, there is a positive outlook for Trevi Therapeutics and the potential success of Haduvio in the treatment of chronic cough.
Bears say
Trevi Therapeutics is facing multiple risks, including clinical/regulatory risk, partnership and financial risk, commercial risk, legal and intellectual property risk, and market share risk. The company's updated IPF cough program, plans to conduct two phase 3 trials, and upcoming investor day may provide more clarity on its clinical development plans for Haduvio, but its success is still subject to regulatory input and dependent on the outcome of GlaxoSmithKline's phase 3 trial of camlipixant. The potential for partnership with GSK and Haduvio being the first and only FDA-approved treatment for RCC could present a positive outlook, but the company remains vulnerable to regulatory and competitive risks.
This aggregate rating is based on analysts' research of Trevi Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
TRVI Analyst Forecast & Price Prediction
Start investing in TRVI
Order type
Buy in
Order amount
Est. shares
0 shares